

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US2005/010266

International filing date: 29 March 2005 (29.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/557,612  
Filing date: 29 March 2004 (29.03.2004)

Date of receipt at the International Bureau: 09 November 2006 (09.11.2006)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1536633

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

October 30, 2006

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/557,612

FILING DATE: March 29, 2004

RELATED PCT APPLICATION NUMBER: PCT/US05/10266

THE COUNTRY CODE AND NUMBER OF YOUR PRIORITY APPLICATION, TO BE USED FOR FILING ABROAD UNDER THE PARIS CONVENTION, IS US60/557,612



Certified by

Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

Please type a plus sign (+) inside this box ☐

PTO/SB/16 (8-00)  
Approved for use through 10/31/2002. OMB 0851-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

INVENTOR(S)					
Given Name (first and middle (if any))		Family Name or Surname		Residence (City and either State or Foreign Country)	
Douglas C. Pinar E.		Wallace Coskun		Irvine, California Long Beach, California	
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (280 characters max)					
METHODS AND APPARATUS FOR DETERMINING MITOCHONDRIAN CONTROL REGION MUTATIONS ASSOCIATED WITH ALZHEIMER'S DISEASE					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input checked="" type="checkbox"/> Customer Number		33197		Place Customer Number Bar Code Label here	
OR Type Customer Number here					
<input checked="" type="checkbox"/> Firm or Individual Name		Robert D. Buyan			
Address		Stout, Uxa, Buyan & Mullins, LLP			
Address		4 Venture, Suite 300			
City		Irvine	State	CA	ZIP 92618
Country		U.S.	Telephone	949-450-1750	Fax 949-450-1764
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification		Number of Pages 30		<input type="checkbox"/> CD(s), Number	
<input type="checkbox"/> Drawing(s)		Number of Sheets		<input checked="" type="checkbox"/> Other (specify)	
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		(Inc. Exhibit A & B); Postcard			
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.		A check or money order is enclosed to cover the filing fees		FILING FEE AMOUNT (\$)	
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number		50-0878		\$80.00	
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input type="checkbox"/> No.					
<input checked="" type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: Nat'l Inst. Health, USA, No. AG13154 and NS21328 and Ellison Medical Foundation, No. Senior Investigator Award					

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME Robert D. Buyan

TELEPHONE

949-450-1750

Date 03/29/04

REGISTRATION NO. 32,460  
(if appropriate)  
Docket Number: UCIVN-061N

## USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C.

P19SMALU/REV05

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: )  
Wallace, et al. )  
Serial No.: To Be Determined )  
Filed: Herewith, March 29, 2004 )  
Title: Methods and Apparatus for )  
Determining Mitochondrial Control )  
Region Mutations Associated with )  
Alzheimer's Disease )

**Transmittal of Provisional Application for Patent**  
**37 CFR 1.53 (b) (2)**

**Express Mail Mailing Label No. EV220346063US**

Mail Stop Provisional Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed, for filing in the United States Patent Office under 37 CFR 1.53 (b)(2),  
please find the following documents:

1. Provisional Patent Application consisting of 30 total pages (including Exhibit A and B), entitled "Methods and Apparatus for Determining Mitochondrial Control Region Mutations Associated with Alzheimer's Disease"
2. A completed Provisional Application Cover Sheet consisting of 1 page;
3. Check No. 3376 in the amount of \$80.00; and
4. A Return Postcard

The inventors of the invention(s) disclosed in this Provisional Patent Application are:

Douglas C. Wallace, Ph.D.

and

Pinar E. Coskun, M.D.

All further correspondence should be mailed to applicant's undersigned counsel at the address shown here below.

Respectfully submitted,

STOUT, UXA, BUYAN & MULLINS, LLP

Date: March 29, 2004



Robert D. Buyan, Reg. No. 32,460


4 Venture, Suite 300  
Irvine, CA 92618  
Telephone: 949/450-1750  
Facsimile: 949/450-1764  
Email: rbuyan@patlawyers.com

---

**CERTIFICATE OF MAILING**

I hereby certify that this transmittal letter and the accompanying Provisional Patent Application entitled "Methods and Apparatus for Determining Mitochondrial Control Region Mutations Associated with Alzheimer's Disease" are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on March 29, 2004 and is addressed to Mail Stop Provisional Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: March 29, 2004

By   
Francine Sanders, Assistant

**PROVISIONAL APPLICATION FOR  
UNITED STATES PATENT**

*by*

**Douglas C. Wallace**

*and*

**Pinar E. Coskun**

*assignors to*

**The Regents of The University of California**

*for*

**METHODS AND APPARATUS FOR DETERMINING  
MITOCHONDRIAL CONTROL REGION MUTATIONS  
ASSOCIATED WITH ALZHEIMER'S DISEASE**

Prepared by Robert D. Buyan  
STOUT, UXA, BUYAN & MULLINS, LLP  
4 Venture, Suite 300  
Irvine, CA 92618  
Telephone: (949) 450-1750  
Facsimile: (949) 450-1764

DOCKET NO. UCIVN-061N

Express Mail No. EV220346063US

# **METHODS AND APPARATUS FOR DETERMINING MITOCHONDRIAL CONTROL REGION MUTATIONS ASSOCIATED WITH ALZHEIMER'S DISEASE**

## **THE INVENTION**

Alzheimer Disease (AD) is the most common form of progressive dementia observed in the elderly. It is associated with the accumulation of  $\beta$ -amyloid ( $A\beta$ ) plaques and neuritic tangles in the brain. However, the cause of late-onset AD is unknown. Also, to date, the molecular cause of late-onset AD has been unknown and, thus, no reliable molecular diagnostic test for late-onset AD has been heretofore known.

Applicant has determined that late-onset AD is associated with the age-related accumulation of somatic mutations in the regulatory elements of the mtDNA control region (CR) that result in a 50% reduction in the light (L)-strand RNA transcripts and a 50% reduction in the mtDNA/nuclear DNA (nDNA) ratio in the cortex of AD brains. Such mutations result in chronic deficiency in mitochondrial oxidative phosphorylation (OXPHOS) and an associated increase in mitochondrial reactive oxygen species (ROS) and, thus, lead to the premature death of the cortical neurons through mitochondrial permeability transition pore (mtPTP)- induced apoptosis. Therefore, the accumulation of somatic mtDNA CR mutations is likely to be the cause of late-onset AD. Hence, the present invention provides reliable molecular diagnostic test for the presence of or pre-disposition to AD.

The mtDNA CR is a 1000 nucleotide pair (np), non-coding, region of the mtDNA that contains the promoters for the initiation of heavy (H) and L-strand transcription ( $P_H$  &  $P_L$ ), the associated mitochondrial transcription factor (mtTFA) binding sites, the three conserved sequence blocks (CSB) I-III, and the origins of H-strand replication ( $O_H$ ). Hence, the CR is the primary site for the regulation of mtDNA transcription and replication.

Specific mtDNA CR mutations have been found to accumulate with age in particular tissues. A T to G transversion at np 414 (T414G) was found to

accumulate with age in human skin fibroblasts (Michikawa et al, 1999, *Science* 286:774-779) and an A189G and a T408A mutation were observed to accumulate in skeletal muscle (Wang et al, 2001, *PNAS* 98:4022-4027). However, the T414G mutation could not be detected in normal brain using  
5 our sensitive protein nucleic acid (PNA)-clamping polymerase chain reaction (PCR) technique (Murdock et al, 2002, *NAR* 28:4350-4355).

However, when we tested for the T414G mutation by PNA-clamping PCR in AD brain frontal cortex, we found that 65% of the AD brains were positive for this mutation while none of the normal control brains had the mutation.  
10 To investigate this phenomenon further, we cloned and sequenced multiple CR clones from the brains of AD patients and age-matched controls. This revealed that the AD brains had a 63% overall increase in CR mutations, and these mutations were preferentially located in sequence motifs in the CR that were known to be involved in regulating mtDNA transcription and regulation.  
15 For example, we found seven mutations each in the CSBI and in the P<sub>H</sub> & P<sub>L</sub> mtTFA elements in AD brains but none in the control brains. Moreover, the age distribution of the AD CR mutations was distinctive, being 65% higher than controls in the ages 59-69, 14% higher in ages 70-79 brains, and 130% higher in ages 80 and older AD brains.

Beyond the overall increase in mtDNA CR somatic mutations in AD brains,  
20 we also discovered two CR mutations that were unique to the brains of AD patients, the T414C and T477C mutations. In addition, mutations at T146C, T152C, A189G, and T195C were more common in AD brains than controls. Finally, the T146C, T195C and T477C mutations increased to very high  
25 levels in the AD brains, in certain cases coming to represent 70-80% of all of the mtDNAs in the patient's brain. Moreover, these mutations were often found together in AD brains, but not in control brains. Finally, these specific mtDNA CR mutations were found at very high frequencies primarily in patients in the age range of 70 to 83 years old, the same range that had the  
30 reduced frequency of more random CR mutations. This implies that there are two classes of AD. In one case, a few CR mutations arise early in



development, become widely disseminated throughout the brain, and then  
clonally amplified in each cell giving rise to an earlier-onset dementia  
associated with a high frequency of a few mutations in the brain. In the other  
case, multiple mutations accumulate, but later in development so that each  
5 individual mutation is confined to a fewer number of cells. When these  
mutations are clonally amplified within their respective cells, each mutation  
can only come to represent a few percent of the total mtDNA CR mutations  
in the brain.

10 In either case, when the percentage of the mutant mtDNAs reaches a high  
enough level within a cell, it inhibits mtDNA transcription and/or replication.  
This leads to reduced L-strand transcription, inhibition of mtDNA replication,  
respiratory deficiency, premature neuronal death and dementia. Hence,  
these data indicate that somatic mtDNA CR region mutations are the cause  
of late-onset AD. Therefore, testing for these mutations becomes and  
15 excellent tool to confirm the diagnosis of AD or to predict those individuals  
who are at risk for the disease though currently pre-symptomatically.

Further aspects and details of the present invention, along with supporting  
experimental data and results, are found in the documents appended hereto  
as Exhibits A and B, the entireties of which are expressly incorporated herein  
20 and for a part of this provisional patent application.

#### **Disclosure Statements in Claim Format:**

25 The invention disclosed herein includes, but is not necessarily limited to  
that recited in the following claims:

1. A method for determining the existence of or potential for development of  
30 Alzheimer's disease (AD) or another neurological disorder associated with the  
development of beta amyloid plaques in a human or veterinary patient, said  
method comprising the step of:

A) determining the presence of mtDNA CR mutations.

2. A method according to Claim 1 above, wherein Step A comprises making a quantitative determination of mtDNS CR mutations.
- 5 3. A method according to Claim 2 further comprising the step of:  
B) comparing the results of the quantitative determination made in Step A with control values representative of patients who do not have and/or do not acquire AD, to determine whether the patient has significantly more mtDNS CR mutations than control.
- 10 4. A method according to Claim 2 further comprising the step of:  
B) comparing the results of the quantitative determination made in Step A with quantitative mtDNS CR values for patients who have and/or acquire AD, to determine whether the patient has or is at risk to develop late onset AD.
- 15 5. A method according to any of Claims 1-4 wherein Step A comprises testing for at least one mutation selected from the group consisting of:  
i. the T4141G mutation;  
ii. the T414C mutation;  
20 iii. the T477C mutation;  
iv. the T146C mutation;  
v. the T152C mutation;  
vi. the A189G mutation; and  
vii. the T195C mutation.
- 25 6. A method according to any of Claims 1-5 wherein Step A is carried out at least in part by a technique selected from the group consisting of:  
i. PNA-clamping PCR;  
ii. oligonucleotide hybridization;  
30 iii. primer extension; and  
iv. restriction digestion

7. A method according to any of Claims 1-6 wherein the determination of Step A is made in a specimen of tissue, cells or body fluid selected from the group consisting of:

- 5 i. brain tissue;
- ii. brain tissue from the frontal cortex;
- iii. nervous tissue;
- iv. nerve cells
- v. blood
- 10 vi. blood cells;
- vii. urine;
- viii. urinary tract cells;
- ix. skin;
- x. skin cells;
- 15 xi. epithelium;
- xii. epithelial cells; and
- xiii. fibroblasts.

8. A test kit comprising reagents and/or materials useable to perform a  
20 method according to any of Claims 1-7.